Compare
Side by side
Pick up to three peptides to see how their mechanisms, studied uses and evidence levels differ. Rows where the entries disagree are marked with a blue edge.
Selected 1 of 3
Comparison
FOXO4-DRI
Mitochondrial & antioxidant
Evidence level
Anecdotal evidence
Approval status
Not approved
Mechanism of action
- 1.Blocks the interaction between FOXO4 and p53 inside senescent cells.
- 2.Senescent cells depend on that interaction to avoid self-destruction; interrupting it makes them undergo apoptosis.
- 3.Non-senescent cells are spared in laboratory models, which is the theoretical advantage over broad senolytics.
- 4.The D-retro-inverso design resists enzyme breakdown, extending its activity.
- 5.Only rodent and cell data exist; human dosing, distribution and safety are unknown.
Studied for
- Cellular senescence and ageing research
- Age-related tissue dysfunction in animal models
- Chemotherapy-induced senescence (research)
- No human trials exist
Reported effects
- Selective death of senescent cells in animal models
- Improved markers of tissue ageing in mice
- No verified human effect
- Injection-site reactions
Side effects
- Not studied in humans
- Theoretical immune reaction to a synthetic D-peptide
- Unknown effect on wound healing and tissue repair, which depend on transient senescence
- Injection-site reactions
Research protocol
Research context only — no human protocol exists. Rodent studies used repeated intraperitoneal or intravenous doses measured in milligrams per kilogram over days. There are no published human safety, dosing or pharmacokinetic data, and self-administration schedules sold online are extrapolations from mice.
Research context only
Evidence justification
The senolytic effect is documented in mice and cell cultures only; there are no human trials of FOXO4-DRI.